Extensive-stage SCLC: consolidation RT boosts survival after chemotherapy

  • Clin Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding consolidative thoracic radiation therapy (TRT) to chemotherapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).
  • Patients who received >10 radiation treatments had better OS than those who received fewer treatments.

Why this matters

  • Studies on the survival benefit of adding TRT to the standard regimen of platinum-based chemotherapy have yielded conflicting results, and the regimen remains underutilized.

Study design

  • 14,367 patients with extensive-stage SCLC from the National Cancer Database.
  • Funding: None disclosed.

Key results

  • 83.7% received CT alone and 16.3% received TRT after CT.
  • OS with TRT+CT was better than CT alone at 12 months (47.7% vs 25.0%) and 5 years (7.1% vs 2.0%).
  • TRT+CT was associated with improved OS compared with CT alone (HR, 1.74; P<.001>
  • OS advantage remained after propensity matching (HR, 1.80; P<.001>
  • Receiving >10 radiation treatments was associated with improved OS before (HR, 1.42; P<.001 and after p propensity matching.>

Limitations

  • Retrospective study.